This study investigates the potential clinical synergy between the PARP inhibitor niraparib (Zejula) and concomitant statins, exploring their combined effects on progression-free survival (PFS) in ...

These shifts highlight specific molecular mechanisms, such as immune activation and structural integrity decline, across various cell types. These findings could help reveal brain regions and ...